The direct renin inhibitor aliskiren, added to standard therapy with renin-angiotensin system blockade, in patients with type 2 diabetes who are at risk for cardiovascular and renal adverse events was not useful at lowering these events and may even be harmful, according to an online study published in the New England Journal of Medicine.
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More